3-({[7-(2-methoxy ethoxy)quinolin-4-yl]methyl}amino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide | 858947-35-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-({[7-(2-methoxy ethoxy)quinolin-4-yl]methyl}amino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide
• 英文别名: 3-[[7-(2-methoxyethoxy)quinolin-4-yl]methylamino]-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide
• CAS: 858947-35-0
• 化学式: C₂₅H₂₂F₃N₃O₄S
• 分子量: 517.529
• InChiKey: GCONIIHWFPDXHO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  36
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  110
• 氢给体数：
  2
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  N-(4-bromo-3-methylphenyl) 3-aminothiophene-2-carboxamide 、 3-({[7-(2-methoxy ethoxy)quinolin-4-yl]methyl}amino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide 、 4-溴-3-甲基苯胺 生成 N-(4-bromo-3-methylphenyl) 3-[(1H-Pyrrolo[2,3-b]pyridin-3-ylmethyl)amino]thiophene-2-carboxamide
  参考文献：
  名称：

  (2-carboxamido)(3-amino) thiophene compounds

  摘要：

  Amidoaryl/amidoheteroaryl取代噻吩，进一步取代一个杂环芳基甲氨基基团，在癌症治疗中是有用的。

  公开号：

  US20050154014A1

文献信息

• (2-CARBOXAMIDO)(3-AMINO) THIOPHENE COMPOUNDS
  申请人：OSI Pharmaceuticals, Inc.

  公开号：EP1807419B1

  公开（公告）日：2009-05-27
• COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN INHIBITOR OF C-KIT
  申请人：Garton Andrew J.

  公开号：US20090136517A1

  公开（公告）日：2009-05-28

  The present invention provides a composition and a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of a combination of an EGFR kinase inhibitor and a KIT kinase inhibitors, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. A preferred example of an EGFR kinase inhibitor that can be used in practicing this invention is the compound erlotinib HCl (also known as TARCEVA®). A preferred example of a KIT kinase inhibitor that can be used in practicing this invention is OSI-930 and OSI-817.
• US7696225B2
  申请人：——

  公开号：US7696225B2

  公开（公告）日：2010-04-13
• [EN] COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN INHIBITOR OF C-KIT<br/>[FR] TRAITEMENT COMBINÉ PAR UN INHIBITEUR DE L'EGFR KINASE ET UN INHIBITEUR DE C-KIT
  申请人：OSI PHARM INC

  公开号：WO2009073139A2

  公开（公告）日：2009-06-11

  The present invention provides a composition and a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of a combination of an EGFR kinase inhibitor and a KIT kinase inhibitors, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. A preferred example of an EGFR kinase inhibitor that can be used in practicing this invention is the compound erlotinib HCl (also known as TARCEV A®). A preferred example of a KIT kinase inhibitor that can be used in practicing this invention is OSI-930 and OSI-817.
• [EN] 2,3-SUBSTITUTED THIOPHENES IN LUNG INFLAMMATION THERAPIES<br/>[FR] THIOPHÈNES 2,3-SUBSTITUÉS DANS DES THÉRAPIES CONTRE UNE INFLAMMATION DES POUMONS
  申请人：OSI PHARM INC

  公开号：WO2009152340A2

  公开（公告）日：2009-12-17

  Methods of treating inflammatory lung conditions comprising administering 2,3- substituted thiophenes of the formula (I).